Hysterectomy Performed on a 47-Year-Old Woman

Poll

A 47-year-old woman undergoes a hysterectomy and a section of the endometrium is sent for analysis. What is your diagnosis?

A 47-year-old woman undergoes a hysterectomy and a section of the endometrium is sent for analysis. According to the histopathology image below, what is your diagnosis?

 

What is your diagnosis?

A. Adenocarcinoma
B. Squamous cell carcinoma
C. Small cell carcinoma
D. Leiomyosarcoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
August 10th 2025
Article
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
August 10th 2025
Podcast
The use of 68Ga-Pentixafor compliments fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

CXCR4 Expression in Gynecologic Malignancies Correlates With OS

Roman Fabbricatore
August 10th 2025
Article
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
August 10th 2025
Podcast
Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

Ariana Pelosci
August 10th 2025
Article
Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.

Simple vs Radical Hysterectomy Shows Comparable Survival in Cervical Cancer

Roman Fabbricatore
August 10th 2025
Article